Matches in SemOpenAlex for { <https://semopenalex.org/work/W2287653609> ?p ?o ?g. }
Showing items 1 to 81 of
81
with 100 items per page.
- W2287653609 endingPage "3054" @default.
- W2287653609 startingPage "3054" @default.
- W2287653609 abstract "3054 Background: HER2 is overexpressed in 25% of breast cancers and plays a role in the malignant transformation of cells. Vaccine-induced immunity against the HER2 ICD correlates with antitumor responses in animal models. DNA-based vaccines offer a strategy to immunize against multiple tumor antigens and are able to elicit both CTL and T helper immune responses. Plasmid DNA can also remain at the vaccine site, providing a constant source of antigen. However, DNA vaccines have been poorly immunogenic due in part to inefficient APC transfection. Intradermal (i.d.) delivery of DNA vaccines with GM-CSF as adjuvant may enhance immunogenicity due to local influx of dermal Langerhans cells. A phase I study was conducted to evaluate the safety and immunogenicity of a DNA-based vaccine encoding the HER2 ICD. Methods: 44 subjects with stage III and IV HER2+ breast cancer in complete remission were enrolled sequentially into 2 vaccine arms (22 subjects/arm) and received 10μg pNGVL3-hICD (Arm 1) or 100μg pNGVL3-hICD (Arm 2). All vaccines were admixed with 100μg GM-CSF and given i.d. monthly for a total of 3 vaccines. Toxicity was assessed at baseline, during vaccination, and at follow-up. Immune responses were assessed with IFN-γ ELISPOT at baseline and post-vaccination. Vaccine site biopsies were analyzed for plasmid persistence via RT-PCR, 1 and 6 months after vaccination. Results: 43 subjects (21 in Arm 1; 22 in Arm 2) completed 3 vaccines. Vaccine-related toxicity in both arms was primarily grade I/II; no cardiac or grade IV toxicity was observed. 13/21 (62%) subjects in Arm 1 developed T-cell immunity, defined as HER2-specific T cell precursors:PBMC, to the HER2 protein (median 1:5,972, range 1:717–1:3,000,000) and to p776, a HER2 pan DR binding epitope (median 1:3,150, range 1:543–1:108,696). 13/19 (68%) subjects in Arm 1 had persistent plasmid DNA at the vaccine site. ELISPOT and RT-PCR analysis for Arm 2 are on-going. Conclusions: Immunization with a DNA plasmid-based HER2 vaccine is safe and immunogenic. Moreover, plasmid DNA persists at the vaccine site post-immunization and HER2+ cancer patients are able to develop immunity to the HER2 ICD. No significant financial relationships to disclose." @default.
- W2287653609 created "2016-06-24" @default.
- W2287653609 creator A5004336666 @default.
- W2287653609 creator A5005473474 @default.
- W2287653609 creator A5018868843 @default.
- W2287653609 creator A5027006941 @default.
- W2287653609 creator A5039848435 @default.
- W2287653609 creator A5053687578 @default.
- W2287653609 creator A5060994391 @default.
- W2287653609 creator A5065386585 @default.
- W2287653609 creator A5085036384 @default.
- W2287653609 creator A5088412399 @default.
- W2287653609 date "2009-05-20" @default.
- W2287653609 modified "2023-09-27" @default.
- W2287653609 title "A phase I study of a DNA plasmid based vaccine encoding the HER2/neu (HER2) intracellular domain (ICD) in subjects with HER2+ breast cancer" @default.
- W2287653609 doi "https://doi.org/10.1200/jco.2009.27.15_suppl.3054" @default.
- W2287653609 hasPublicationYear "2009" @default.
- W2287653609 type Work @default.
- W2287653609 sameAs 2287653609 @default.
- W2287653609 citedByCount "2" @default.
- W2287653609 countsByYear W22876536092021 @default.
- W2287653609 crossrefType "journal-article" @default.
- W2287653609 hasAuthorship W2287653609A5004336666 @default.
- W2287653609 hasAuthorship W2287653609A5005473474 @default.
- W2287653609 hasAuthorship W2287653609A5018868843 @default.
- W2287653609 hasAuthorship W2287653609A5027006941 @default.
- W2287653609 hasAuthorship W2287653609A5039848435 @default.
- W2287653609 hasAuthorship W2287653609A5053687578 @default.
- W2287653609 hasAuthorship W2287653609A5060994391 @default.
- W2287653609 hasAuthorship W2287653609A5065386585 @default.
- W2287653609 hasAuthorship W2287653609A5085036384 @default.
- W2287653609 hasAuthorship W2287653609A5088412399 @default.
- W2287653609 hasConcept C121608353 @default.
- W2287653609 hasConcept C126322002 @default.
- W2287653609 hasConcept C147483822 @default.
- W2287653609 hasConcept C167508917 @default.
- W2287653609 hasConcept C203014093 @default.
- W2287653609 hasConcept C22070199 @default.
- W2287653609 hasConcept C2776090121 @default.
- W2287653609 hasConcept C2777863537 @default.
- W2287653609 hasConcept C2779053233 @default.
- W2287653609 hasConcept C2780801004 @default.
- W2287653609 hasConcept C2780868878 @default.
- W2287653609 hasConcept C530470458 @default.
- W2287653609 hasConcept C71924100 @default.
- W2287653609 hasConcept C8891405 @default.
- W2287653609 hasConceptScore W2287653609C121608353 @default.
- W2287653609 hasConceptScore W2287653609C126322002 @default.
- W2287653609 hasConceptScore W2287653609C147483822 @default.
- W2287653609 hasConceptScore W2287653609C167508917 @default.
- W2287653609 hasConceptScore W2287653609C203014093 @default.
- W2287653609 hasConceptScore W2287653609C22070199 @default.
- W2287653609 hasConceptScore W2287653609C2776090121 @default.
- W2287653609 hasConceptScore W2287653609C2777863537 @default.
- W2287653609 hasConceptScore W2287653609C2779053233 @default.
- W2287653609 hasConceptScore W2287653609C2780801004 @default.
- W2287653609 hasConceptScore W2287653609C2780868878 @default.
- W2287653609 hasConceptScore W2287653609C530470458 @default.
- W2287653609 hasConceptScore W2287653609C71924100 @default.
- W2287653609 hasConceptScore W2287653609C8891405 @default.
- W2287653609 hasIssue "15_suppl" @default.
- W2287653609 hasLocation W22876536091 @default.
- W2287653609 hasOpenAccess W2287653609 @default.
- W2287653609 hasPrimaryLocation W22876536091 @default.
- W2287653609 hasRelatedWork W1481917790 @default.
- W2287653609 hasRelatedWork W2009090497 @default.
- W2287653609 hasRelatedWork W2043775195 @default.
- W2287653609 hasRelatedWork W2050796469 @default.
- W2287653609 hasRelatedWork W2090698640 @default.
- W2287653609 hasRelatedWork W2095304551 @default.
- W2287653609 hasRelatedWork W2357951527 @default.
- W2287653609 hasRelatedWork W2411712784 @default.
- W2287653609 hasRelatedWork W2594077466 @default.
- W2287653609 hasRelatedWork W3109192410 @default.
- W2287653609 hasVolume "27" @default.
- W2287653609 isParatext "false" @default.
- W2287653609 isRetracted "false" @default.
- W2287653609 magId "2287653609" @default.
- W2287653609 workType "article" @default.